2030年欧洲肌少症治疗市场规模和行业统计

欧洲肌肉减少症治疗市场分析和规模

推动欧洲肌肉减少症治疗市场增长的主要因素是肌肉减少症患病率的上升。此外，人们对肌肉减少症及其对健康的不利影响的认识不断提高是推动市场增长的另一个关键因素。营养不良和久坐不动等生活方式因素也会影响市场。然而，缺乏标准化诊断以及治疗和干预的高成本预计将抑制市场增长。

Data Bridge Market Research分析，欧洲肌肉减少症治疗市场预计到2030年将达到1,033,968.39万美元的价值，预测期内的复合年增长率为4.6%。

本市场报告还深入介绍了定价分析和技术进步。

报告指标	细节
预测期	2023 至 2030 年
基准年	2022
历史岁月	2021（可定制为 2015 - 2020）
定量单位	收入（千美元）、销量（单位）、定价（美元）
涵盖的领域	治疗类型（药物、维生素/膳食补充剂等）、类型（原发性肌肉减少症和继发性肌肉减少症）、阶段（前期肌肉减少症、肌肉减少症和重度肌肉减少症）、给药途径（口服、注射等）、性别（男性和女性）、最终用户（医院、专科诊所、家庭医疗保健等）、分销渠道（直接招标、零售销售等）
覆盖国家	德国、法国、英国、意大利、西班牙、俄罗斯、土耳其、比利时、荷兰、瑞士、丹麦、挪威、瑞典、波兰、芬兰和欧洲其他地区
涵盖的市场参与者	雅培、雀巢健康科学（雀巢公司的子公司）、诺华公司、赛诺菲、Haleon 集团、巴斯夫 SE、帝斯曼、Fermenta Biotech Limited、AstaReal Co., Ltd.、Metagenics、Wellona Pharma、The Vitamin Company India、Healing Pharma India Pvt. Ltd.、OPKO Health, Inc.、NMD PHARMA A/S、Regeneron Pharmaceuticals Inc.、Biophytis、ARMGO Pharma, Inc. Rejuvenate Biomed NV. 等等

市场定义

肌肉减少症治疗是指与旨在预防、控制或治疗肌肉减少症的产品和服务相关的商业领域。肌肉减少症是一种与年龄有关的进行性疾病，其特征是骨骼肌质量、力量和功能的丧失，通常始于 30 岁左右，并在 60 岁后加速。

肌肉减少症对个人的整体健康和生活质量有重大影响。肌肉力量和耐力会相应下降，使日常任务更具挑战性，并且随着肌肉质量的下降，跌倒和骨折的风险也会增加。此外，肌肉减少症还会导致代谢变化、胰岛素抵抗和肥胖可能性增加。

欧洲肌肉减少症治疗市场动态

本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容：

驱动程序

肌肉减少症患病率上升

肌肉减少症是一种以肌肉质量、力量和功能下降为特征的疾病，尤其发生在老年人身上。随着年龄的增长，老年人的肌肉质量和功能会逐渐下降，这导致他们容易患上肌肉减少症。随着世界人口老龄化，患上肌肉减少症的人数正在稳步增加。这种人口结构的变化直接推动了对肌肉减少症治疗方案的需求。该病的患病率不断上升意味着需要诊断和治疗的人数越来越多，从而为肌肉减少症治疗市场创造了更大的患者群体。

随着医疗保健和医学的进步，人们的寿命越来越长。然而，随着年龄的增长，人们患上肌肉减少症的可能性也越来越大。这种较长的预期寿命导致该病的总体患病率上升。糖尿病、心血管疾病和癌症等慢性疾病会导致肌肉损失并导致肌肉减少症的发生。这些疾病发病率的上升直接影响了肌肉减少症患病率的上升。

随着世界人口不断老龄化，对预防或控制肌肉减少症的有效干预措施的需求预计将增加，从而促进肌肉减少症治疗领域的研究、开发和创新，预计这将推动市场增长。

人们对肌肉减少症及其对健康的有害影响的认识不断提高

人们对肌肉减少症及其对健康的有害影响的认识不断提高，这是医疗保健和老龄化领域的重大发展。与肌肉减少症相关的研究和出版物显著增加。科学研究、医学期刊和出版物为医疗保健专业人员提供了有关该病的患病率、诊断和后果的宝贵信息。医学院和培训项目已将肌肉减少症纳入课程。这确保医疗保健专业人员（包括医生、护士和理疗师）接受有关肌肉减少症、其风险因素和管理策略的教育。

机会

主要市场参与者的战略举措

肌肉减少症治疗市场正在经历大幅增长，因为它是一种与年龄有关的渐进性疾病，其特征是肌肉质量、力量和功能的丧失。这是一个重大的健康问题，尤其是对老年人来说，因为它会导致行动能力下降、跌倒和骨折风险增加以及整体生活质量下降，因此主要市场参与者正在积极采取战略举措进行产品开发。从而为市场扩张和发展开辟了机会。

战略计划包括与研究机构、医疗保健组织和学术中心的合作和伙伴关系。市场参与者可以利用他们的知识和资源，通过与该领域的专家合作来加速肌肉减少症治疗的开发和商业化。此类合作促进了知识交流、接触临床试验患者群体以及汇集专业知识以推动市场创新。

克制/挑战

缺乏标准化诊断

缺乏标准化诊断标准可能会导致延迟诊断或漏诊肌肉减少症病例。医疗保健专业人员可能不会定期筛查该疾病，尤其是成年人，这可能会妨碍早期干预和治疗。如果没有标准化诊断，医疗保健提供者可能会使用不同的标准和方法来识别肌肉减少症。这种不一致可能导致报告的肌肉减少症患病率和确诊病例数存在差异，这使得评估真正的市场规模和治疗需求变得具有挑战性。

肌肉减少症是一种多方面的疾病，会根据年龄、性别和合并症等因素对个体产生不同的影响。患者群体可能各不相同，因此，如果没有标准化的诊断标准，就很难进行临床试验和研究以准确评估治疗效果。肌肉减少症治疗的临床试验可能使用不同的诊断标准，因此很难比较不同研究的结果。这种标准化的缺乏可能会阻碍监管机构开发和批准新的治疗方法。

最新动态

2023 年 2 月，雀巢健康科学宣布与 EraCal Therapeutics 达成研究合作，旨在寻找与控制食物摄入相关的新型营养保健品。这将增加公司的产品组合和整体收入。
2022年11月，雅培宣布因其改变生活的技术而荣获美国消费技术协会（CTA）颁发的三项CES 2023创新奖，这些技术正在推动健康科技行业的发展并改善全球人民的生活。

欧洲肌肉减少症治疗市场范围

欧洲肌肉减少症治疗市场分为七个显著的细分市场，例如治疗类型、类型、阶段、给药途径、性别、最终用户和分销渠道。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，以确定核心市场应用。

治疗类型

维生素/膳食补充剂
药物
其他的

根据治疗类型，市场分为药物、维生素/膳食补充剂和其他。

类型

原发性肌肉减少症
继发性肌肉减少症

根据类型，市场分为原发性肌肉减少症和继发性肌肉减少症。

阶段

肌肉减少症前期
肌肉减少症
严重肌肉减少症

根据阶段，市场分为肌少症前期、肌少症和重度肌少症。

给药途径

口服
注射剂
其他的

根据给药途径，市场分为口服、注射和其他。

性别

男性
女性

根据性别，市场分为男性和女性。

最终用户

医院
专科诊所
家庭医疗保健
其他的

根据最终用户，市场分为医院、专科诊所、家庭医疗保健和其他。

分销渠道

直接招标
零售销售
其他的

根据分销渠道，市场分为直接招标、零售和其他。

欧洲肌肉减少症治疗市场区域分析/见解

对欧洲肌肉减少症治疗市场进行了分析，并按国家、治疗类型、类型、阶段、给药途径、性别、最终用户和分销渠道提供了市场规模洞察和趋势。

本市场报告涵盖的国家包括德国、法国、英国、意大利、西班牙、俄罗斯、土耳其、比利时、荷兰、瑞士、丹麦、挪威、瑞典、波兰、芬兰和欧洲其他地区。

由于各制造商的投资水平较高且该地区对药品制造的需求不断增加，预计德国将主导欧洲肌肉减少症治疗市场。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和市场监管变化。下游和上游价值链分析、技术趋势、波特五力分析和案例研究等数据点是用于预测各个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了欧洲品牌的存在和可用性以及由于来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税的影响和贸易路线。

竞争格局和欧洲肌肉减少症治疗市场份额分析

欧洲肌肉减少症治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、新市场计划、区域存在、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度以及应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

欧洲肌肉减少症治疗市场的一些主要市场参与者包括雅培、雀巢健康科学（雀巢公司的子公司）、诺华公司、赛诺菲、海利昂集团、巴斯夫欧洲公司、帝斯曼、Fermenta Biotech Limited、AstaReal Co., Ltd.、Metagenics、Wellona Pharma、The Vitamin Company India、Healing Pharma India Pvt. Ltd. 等。

SKU-70293

Get online access to the report on the World's First Market Intelligence Cloud

Click on image to enlarge

Interactive Data Analysis Dashboard
Company Analysis Dashboard for high growth potential opportunities
Research Analyst Access for customization & queries
Competitor Analysis with Interactive dashboard
Latest News, Updates & Trend analysis
Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Request for Demo

表格列表

TABLE 1 CURRENT STATUS OF THE DEVELOPMENT OF DRUG FOR SARCOPENIA TREATMENT

TABLE 2 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 3 EUROPE VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 4 EUROPE VITAMIN/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 5 EUROPE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 6 EUROPE MEDICATINONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 7 EUROPE OFF-LABLE DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 8 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 9 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 10 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 11 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 12 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 13 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 14 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 15 EUROPE PRE-SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 16 EUROPE SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 17 EUROPE SEVERE SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 18 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 19 EUROPE ORAL IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 20 EUROPE INJECTABLES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 21 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 22 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 23 EUROPE MALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 24 EUROPE FEMALE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 25 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 26 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 27 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 28 EUROPE SPECIALTY CLINICS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 29 EUROPE HOME HEALTHCARE IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 30 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 31 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 32 EUROPE DIRECT TENDER IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 33 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 34 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 35 EUROPE OTHERS IN SARCOPENIA TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND)

TABLE 36 EUROPE SARCOPENIA TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND)

TABLE 37 EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 38 EUROPE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 39 EUROPE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 40 EUROPE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 41 EUROPE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 42 EUROPE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 43 EUROPE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 44 EUROPE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 45 EUROPE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 46 EUROPE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 47 EUROPE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 48 EUROPE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 49 EUROPE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 50 EUROPE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 51 EUROPE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 52 GERMANY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 53 GERMANY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 54 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 55 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 56 GERMANY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 57 GERMANY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 58 GERMANY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 59 GERMANY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 60 GERMANY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 61 GERMANY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 62 GERMANY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 63 GERMANY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 64 GERMANY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 65 GERMANY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 66 GERMANY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 67 GERMANY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 68 FRANCE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 69 FRANCE MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 70 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 71 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 72 FRANCE OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 73 FRANCE VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 74 FRANCE SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 75 FRANCE PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 76 FRANCE SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 77 FRANCE SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 78 FRANCE SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 79 FRANCE SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 80 FRANCE SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 81 FRANCE HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 82 FRANCE SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 83 FRANCE RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 84 U.K. SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 85 U.K. MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 86 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 87 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 88 U.K. OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 89 U.K. VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 90 U.K. SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 91 U.K. PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 92 U.K. SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 93 U.K. SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 94 U.K. SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 95 U.K. SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 96 U.K. SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 97 U.K. HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 98 U.K. SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 99 U.K. RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 100 ITALY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 101 ITALY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 102 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 103 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 104 ITALY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 105 ITALY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 106 ITALY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 107 ITALY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 108 ITALY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 109 ITALY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 110 ITALY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 111 ITALY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 112 ITALY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 113 ITALY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 114 ITALY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 115 ITALY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 116 SPAIN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 117 SPAIN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 118 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 119 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 120 SPAIN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 121 SPAIN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 122 SPAIN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 123 SPAIN PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 124 SPAIN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 125 SPAIN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 126 SPAIN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 127 SPAIN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 128 SPAIN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 129 SPAIN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 130 SPAIN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 131 SPAIN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 132 RUSSIA SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 133 RUSSIA MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 134 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 135 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 136 RUSSIA OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 137 RUSSIA VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 138 RUSSIA SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 139 RUSSIA PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 140 RUSSIA SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 141 RUSSIA SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 142 RUSSIA SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 143 RUSSIA SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 144 RUSSIA SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 145 RUSSIA HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 146 RUSSIA SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 147 RUSSIA RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 148 TURKEY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 149 TURKEY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 150 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 151 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 152 TURKEY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 153 TURKEY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 154 TURKEY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 155 TURKEY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 156 TURKEY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 157 TURKEY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 158 TURKEY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 159 TURKEY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 160 TURKEY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 161 TURKEY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 162 TURKEY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 163 TURKEY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 164 BELGIUM SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 165 BELGIUM MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 166 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 167 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 168 BELGIUM OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 169 BELGIUM VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 170 BELGIUM SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 171 BELGIUM PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 172 BELGIUM SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 173 BELGIUM SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 174 BELGIUM SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 175 BELGIUM SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 176 BELGIUM SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 177 BELGIUM HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 178 BELGIUM SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 179 BELGIUM RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 180 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 181 NETHERLANDS MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 182 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 183 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 184 NETHERLANDS OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 185 NETHERLANDS VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 186 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 187 NETHERLANDS PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 188 NETHERLANDS SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 189 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 190 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 191 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 192 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 193 NETHERLANDS HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 194 NETHERLANDS SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 195 NETHERLANDS RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 196 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 197 SWIZTERLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 198 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 199 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 200 SWIZTERLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 201 SWIZTERLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 202 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 203 SWIZTERLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 204 SWIZTERLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 205 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 206 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 207 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 208 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 209 SWIZTERLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 210 SWIZTERLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 211 SWIZTERLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 212 DENMARK SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 213 DENMARK MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 214 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 215 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 216 DENMARK OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 217 DENMARK VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 218 DENMARK SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 219 DENMARK PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 220 DENMARK SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 221 DENMARK SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 222 DENMARK SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 223 DENMARK SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 224 DENMARK SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 225 DENMARK HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 226 DENMARK SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 227 DENMARK RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 228 NORWAY SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 229 NORWAY MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 230 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 231 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 232 NORWAY OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 233 NORWAY VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 234 NORWAY SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 235 NORWAY PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 236 NORWAY SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 237 NORWAY SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 238 NORWAY SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 239 NORWAY SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 240 NORWAY SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 241 NORWAY HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 242 NORWAY SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 243 NORWAY RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 244 SWEDEN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 245 SWEDEN MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 246 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 247 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 248 SWEDEN OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 249 SWEDEN VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 250 SWEDEN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 251 SWEDEN SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 252 SWEDEN SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 253 SWEDEN SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 254 SWEDEN SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 255 SWEDEN SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 256 SWEDEN HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 257 SWEDEN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 258 SWEDEN RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 259 POLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 260 POLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 261 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 262 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 263 POLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 264 POLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 265 POLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 266 POLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 267 POLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 268 POLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 269 POLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 270 POLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 271 POLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 272 POLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 273 POLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 274 POLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 275 FINLAND SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 276 FINLAND MEDICATIONS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 277 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 278 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (VOLUME)

TABLE 279 FINLAND OFF-LABEL DRUGS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (ASP)

TABLE 280 FINLAND VITAMINS/DIETARY SUPPLEMENTS IN SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

TABLE 281 FINLAND SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 282 FINLAND PRIMARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 283 FINLAND SECONDARY SARCOPENIA IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 284 FINLAND SARCOPENIA TREATMENT MARKET, BY STAGES, 2021-2030 (USD THOUSAND)

TABLE 285 FINLAND SARCOPENIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD THOUSAND)

TABLE 286 FINLAND SARCOPENIA TREATMENT MARKET, BY GENDER, 2021-2030 (USD THOUSAND)

TABLE 287 FINLAND SARCOPENIA TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND)

TABLE 288 FINLAND HOSPITALS IN SARCOPENIA TREATMENT MARKET, BY TYPE, 2021-2030 (USD THOUSAND)

TABLE 289 FINLAND SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 290 FINLAND RETAIL SALES IN SARCOPENIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND)

TABLE 291 REST OF EUROPE SARCOPENIA TREATMENT MARKET, BY TREATMENT TYPE, 2021-2030 (USD THOUSAND)

图片列表

FIGURE 1 EUROPE SARCOPENIA TREATMENT MARKET: SEGMENTATION

FIGURE 2 EUROPE SARCOPENIA TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 EUROPE SARCOPENIA TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 EUROPE SARCOPENIA TREATMENT MARKET: EUROPE VS REGIONAL MARKET ANALYSIS

FIGURE 5 EUROPE SARCOPENIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE SARCOPENIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 EUROPE SARCOPENIA TREATMENT MARKET: MARKET END USERS COVERAGE GRID

FIGURE 8 EUROPE SARCOPENIA TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE SARCOPENIA TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 EUROPE SARCOPENIA TREATMENT MARKET: SEGMENTATION

FIGURE 11 THE RISING PREVALENCE OF SARCOPENIA AND GROWING AWARENESS OF SARCOEPNIA AND ITS DETRIMENTAL EFFECT ON HEALTH ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE SARCOPENIA TREATMENT MARKET FROM 2023 TO 2030

FIGURE 12 VITAMIN/DIETARY SUPPLEMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE PRECLINICAL MARKET IN 2023 AND 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE SARCOPENIA TREATMENT MARKET

FIGURE 14 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2022

FIGURE 15 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, 2023-2030 (USD THOUSAND)

FIGURE 16 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT TYPE, CAGR (2023-2030)

FIGURE 17 EUROPE SARCOPENIA TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 18 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, 2022

FIGURE 19 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, 2023-2030 (USD THOUSAND)

FIGURE 20 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, CAGR (2023-2030)

FIGURE 21 EUROPE SARCOPENIA TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 22 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, 2022

FIGURE 23 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, 2023-2030 (USD THOUSAND)

FIGURE 24 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, CAGR (2023-2030)

FIGURE 25 EUROPE SARCOPENIA TREATMENT MARKET: BY STAGES, LIFELINE CURVE

FIGURE 26 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 27 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030)

FIGURE 28 EUROPE SARCOPENIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION (2023-2030)

FIGURE 29 EUROPE SARCOPENIA TREATMENT MARKET: LIFELINE CURVE

FIGURE 30 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, 2022

FIGURE 31 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, 2023-2030 (USD THOUSAND)

FIGURE 32 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, CAGR (2023-2030)

FIGURE 33 EUROPE SARCOPENIA TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 34 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, 2022

FIGURE 35 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, 2023-2030 (USD THOUSAND)

FIGURE 36 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, CAGR (2023-2030)

FIGURE 37 EUROPE SARCOPENIA TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 38 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 39 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 40 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 41 EUROPE SARCOPENIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD THOUSAND)

FIGURE 42 EUROPE SARCOPENIA TREATMENT MARKET: SNAPSHOT (2022)

FIGURE 43 EUROPE SARCOPENIA TREATMENT MARKETSTRUCTURAL HEALTH MONITORING MARKET: COMPANY SHARE 2022 (%)

查看详细信息

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

How big is the Europe sarcopenia treatment market?

The Europe sarcopenia treatment market size will be worth USD 1,033,968.39 thousand by 2030.

What is the growth rate of the Europe sarcopenia treatment market?

The growth rate of the Europe sarcopenia treatment market is 4.6% by the forecasted time period.

What are the growth drivers of the Europe sarcopenia treatment market?

The rising prevalence of sarcopenia & growing awareness of sarcopenia and its detrimental effects on health are the growth drivers of the Europe sarcopenia treatment market.

What are the factors on which the Europe sarcopenia treatment market research is based on?

Treatment type, type, stages, route of administration, gender, end user, and distribution channel are the factors on which the Europe sarcopenia treatment market research is based.

Which are the major companies in the Europe sarcopenia treatment market?

Major companies in the Europe sarcopenia treatment market are Abbott., Nestlé Health Science (A subsidary of Nestlé S.A.), Novartis AG, Sanofi, Haleon Group of Companies., BASF SE, DSM, Fermenta Biotech Limited, AstaReal Co., Ltd., Metagenics, Wellona Pharma, The Vitamin Company India & Healing Pharma India Pvt. Ltd.

Forecast Period	2023 –2030
Market Size (Base Year)	USD MILLION Request
Market Size (Forecast Year)	USD 1,033,968.39
CAGR	4.60 %
Major Markets Players	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Request For Unlock

欧洲肌肉减少症治疗市场 – 行业趋势和 2030 年预测

欧洲肌肉减少症治疗市场 – 行业趋势和 2030 年预测

Europe Sarcopenia Treatment Market

CAGR : 4.60 %

欧洲肌肉减少症治疗市场分析和规模

欧洲肌肉减少症治疗市场动态

欧洲肌肉减少症治疗市场范围

欧洲肌肉减少症治疗市场区域分析/见解

竞争格局和欧洲肌肉减少症治疗市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

报告

市场洞察

支持

解决方案

欧洲肌肉减少症治疗市场 – 行业趋势和 2030 年预测

欧洲肌肉减少症治疗市场 – 行业趋势和 2030 年预测

Europe Sarcopenia Treatment Market

CAGR : 4.60 %

欧洲肌肉减少症治疗市场分析和规模

欧洲肌肉减少症治疗市场动态

欧洲肌肉减少症治疗市场范围

欧洲肌肉减少症治疗市场区域分析/见解

竞争格局和欧洲肌肉减少症治疗市场份额分析

Get online access to the report on the World's First Market Intelligence Cloud

目录

表格列表

图片列表

研究方法

可定制

Frequently Asked Questions

浏览相关页面